Clinical Trials Logo

Clinical Trial Summary

The management of a patient with shock is based on improving tissue oxygenation through hemodynamic optimization. Lactate is a marker of tissue hypoperfusion commonly used in the ICU. In principle, hyperlactatemia can be caused by either increased tissue production (tissue hypoperfusion: type A), decreased lactate uptake (type B), or a combination of both mechanisms. It is important to correctly determine the cause(s) of hyperlactatemia, as this determines the treatment (expanders, inotrope, vasopressor, blood derivative transfusion), and the patient's morbidity and mortality. A classic example of this concept is volume expanders, which are frequently used to correct hyperlactatemia secondary to tissue hypoperfusion, but are associated with mortality if used excessively (fluid overload). In clinical practice, it is difficult to differentiate the exact causes of hyperlactatemia (type A and type B). From work carried out over the last 20 years in septic shock and then in other states of shock and in the operating theatre, it has been shown that the arteriovenous CO2 gradient (pCO2gap) measured from arterial and venous blood gases is a marker of tissue hypoperfusion with better predictive ability than the usual markers (clinical examination, SVO2....). Furthermore, when we relate pCO2gap to the arteriovenous O2 difference (pCO2gap /C(a-v)O2), this ratio allows us to distinguish with greater accuracy between states of acute circulatory failure associated with anaerobiosis (tissue hypoperfusion, type A) and those related to the underlying disease. Also, several studies have demonstrated a strong ability of the pCO2gap and the pCO2gap/CavO2 ratio to predict the severity of shock, mortality of the shock patient, hyperlactatemia, and correction of hyperlactatemia with hemodynamic treatment. As a result, many authors have proposed algorithms for the management of shock patients based on the measurement of these CO2-derived indexes. The hypothesis of this study is that the use of an algorithm based on CO2gap and the CO2gap/CavO2 ratio is superior in terms of correction of hyperlactatemia to usual practice based on clinical and macro-hemodynamics.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05032521
Study type Interventional
Source Centre Hospitalier Universitaire Dijon
Contact Pierre-Grégoire GUINOT
Phone 03.80.28.13. 09
Email [email protected]
Status Not yet recruiting
Phase Phase 4
Start date September 2021
Completion date September 2024

See also
  Status Clinical Trial Phase
Completed NCT03025659 - Lactate Acidosis in Postoperative Hearts
Not yet recruiting NCT04315623 - RCA for CRRT in Hyperlactatemia Patient With Increased Bleeding Risk N/A
Active, not recruiting NCT04710875 - The Role of Lactate in Lipolysis and Catabolism in Humans N/A
Completed NCT03078712 - Early Goal Directed Therapy Using a Physiological Holistic View. The ANDROMEDA-SHOCK Study N/A
Recruiting NCT03762005 - Peripheral Perfusion Versus Lactate Targeted Fluid Resuscitation in Septic Shock N/A
Recruiting NCT04410315 - Hyperlactatemia During and After Tumorcraniotomy
Completed NCT02950753 - Does Intravenous Lactated Ringer Solution Raise Measured Serum Lactate? Early Phase 1
Recruiting NCT03649009 - Thiamine As An Adjuvant Therapy For Hyperlactatemia In Septic Shock Patients N/A
Recruiting NCT04388267 - Fluid REsponsiveness and Arterial ELASTANCE in Patients With Septic Shock or After Aortic Surgery
Not yet recruiting NCT04284722 - Perioperative Continuation of Metformin Therapy in Patients With Typ 2 Diabetes Mellitus Undergoing Non-cardiac Surgery Phase 4
Completed NCT00270673 - Early Lactate-Directed Therapy in the Intensive Care Unit (ICU) Phase 3
Not yet recruiting NCT04046861 - Influence of High Vitamin C Dose on Lactate During and After Extracorporeal Circulation N/A
Completed NCT00390273 - Effect of Metformin on Lactate Metabolism Phase 1/Phase 2
Completed NCT00471614 - Effects of Uridine Supplementation on Metabolic Side Effects of Stavudine and Zidovudine Phase 2
Completed NCT04299815 - Lactate in the Gut N/A